#4d molecular therapeutics phone plus#
#4d molecular therapeutics phone free#

Each of the company logos represented herein are trademarks of Microsoft Corporation Dow Jones & Company Nasdaq, Inc. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Marinus Pharmaceuticals' revenues are expected to be $5.33 million, down 62.5% from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This epilepsy drug developer is expected to post quarterly loss of $0.77 per share in its upcoming report, which represents a year-over-year change of -48.1%. The results are expected to be released on May 11.

#4d molecular therapeutics phone free#

Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.Īnother stock from the same industry, Marinus Pharmaceuticals ( MRNS Quick Quote MRNS - Free Report), has yet to report results for the quarter ended March 2023.

#4d molecular therapeutics phone plus#

In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 45% of the 250 plus Zacks industries. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. The current consensus EPS estimate is -$0.85 on $1.44 million in revenues for the coming quarter and -$3.56 on $5.67 million in revenues for the current fiscal year. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. So, the shares are expected to perform in line with the market in the near future. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Īhead of this earnings release, the estimate revisions trend for 4D Molecular Therapeutics, Inc. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Įmpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? What's Next for 4D Molecular Therapeutics, Inc. Shares have lost about 22% since the beginning of the year versus the S&P 500's gain of 7.3%. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.ĤD Molecular Therapeutics, Inc. The company has not been able to beat consensus revenue estimates over the last four quarters. This compares to year-ago revenues of $1.22 million. , which belongs to the Zacks Medical - Drugs industry, posted revenues of $0.3 million for the quarter ended March 2023, missing the Zacks Consensus Estimate by 79.49%. Over the last four quarters, the company has surpassed consensus EPS estimates just once.ĤD Molecular Therapeutics, Inc. These figures are adjusted for non-recurring items.Ī quarter ago, it was expected that this company would post a loss of $0.75 per share when it actually produced a loss of $0.84, delivering a surprise of -12%. This compares to loss of $0.82 per share a year ago. ( FDMT Quick Quote FDMT - Free Report) came out with a quarterly loss of $0.88 per share in line with the Zacks Consensus Estimate.